Patients with Wegener's granulomatosis: A long-term follow-up study

Clinical and Experimental Rheumatology

Volumn 28, Issue 1 SUPPL. 57, 2010, Pages

  De Leeuw, Karina ^a   Van Der Graaf, Anne Marijn ^a   Bijzet, Johan ^a   Stegeman, Coen A ^a   Smit, Andries J ^b   Kallenberg, Cees G ^a   Bijl, Marc ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atherosclerosis; Ultrasound; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; THROMBOMODULIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; MALE; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEGENER GRANULOMATOSIS; BLOOD; ECHOGRAPHY; INTIMA; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK FACTOR; TUNICA MEDIA; VASCULAR ENDOTHELIUM; BLOOD PRESSURE; COMMON CAROTID ARTERY; DISEASE ASSOCIATION; ENDOTHELIUM; KIDNEY FUNCTION; PREVALENCE; ULTRASOUND; VISUAL ANALOG SCALE;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA; VASCULAR CELL ADHESION MOLECULE-1; VON WILLEBRAND FACTOR; WEGENER GRANULOMATOSIS;

EID: 77954579841     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. LIBBY P, RIDKER PM, MASERI A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
2. ROSS R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. ALBERT MA, GLYNN RJ, RIDKER PM: Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.
4. RIDKER PM, HENNEKENS CH, BURING JE, RIFAI N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
5. HIND CR, WINEARLS CG, LOCKWOOD CM, REES AJ, PEPYS MB: Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol 1984; 21: 341-5.
6. STEGEMAN CA, TERVAERT JW, HUITEMA MG, JONG PE DE, KALLENBERG CG: Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during followup. Arthritis Rheum 1994; 37: 1228-35.
7. BOOTH AD, WALLACE S, MCENIERY CM et al.: Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004; 50: 581-8.
8. BOOTH AD, JAYNE DR, KHARBANDA RK et al.: Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109: 1718-23.
9. FILER AD, GARDNER-MEDWIN JM, THAMBYRAJAH J et al.: Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003; 62: 162-7.
10. NIENHUIS H, DE LEEUW K, SMIT AJ et al.: Enhanced endothelium-dependent microvascular responses in patients with Wegener's granulomatosis. J Rheumatol 2007; 34: 1875-81.
11. GHIADONI L, MOSCA M, TANI C, VIRDIS A, TADDEI S, BOMBARDIERI S: Clinical and methodological aspects of endothelial function in patients with systemic autoimmune diseases. Clin Exp Rheumatol 2008; 26: 680-7.
12. DE LEEUW K, SANDERS JS, STEGEMAN C, SMIT A, KALLENBERG CG, BIJL M: Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005; 64: 753-9.
13. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8.
14. DE GROOT E, JUKEMA JW, MONTAUBAN VAN SWIJNDREGT AD et al.: B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31: 1561-7.
15. SRAMEK A, BOSCH JG, REIBER JH, VAN OOSTAYEN JA, ROSENDAAL FR: Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000; 35: 699-706.
16. MACKINNON AD, JERRARD-DUNNE P, SITZER M, BUEHLER A, VON KS, MARKUS HS: Rates and determinants of site-specific progression of carotid artery intima-media thickness: the carotid atherosclerosis progression study. Stroke 2004; 35: 2150-4.
17. MUKHTYAR C, LUQMANI R: Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin Exp Rheumatol 2007; 25: 120-9.
18. GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ, MARTIN J, LLORCA J. GONZALEZ-GAY MA: Atherosclerosis in patients with biopsyproven giant cell arteritis. Arthritis Rheum 2007; 57: 1481-6.
19. GONZALEZ-GAY MA,GONZALEZ-JUANATEY C, PINEIRO A, GARCIA-PORRUA C, TESTA A, LLORCA J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1219-23.
20. WAJED J, AHMAD Y, DURRINGTON PN, BRUCE IN: Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology (Oxford) 2004; 43: 7-12.
21. RAHMAN A, BESSANT R, ISENBERG DA: What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus? Lupus 2006; 15: 697-9.
22. SCHATTNER A, LIANG MH: The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 2003; 163: 1507-10.
23. RIDKER PM, RIFAI N, ROSE L, BURING JE, COOK NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
24. PAPAGIANNI A, DOVAS S, BANTIS C et al.: Carotid atherosclerosis and endothelial cell adhesion molecules as predictors of long-term outcome in chronic hemodialysis patients. Am J Nephrol 2008; 28: 265-74.
25. SOEDAMAH-MUTHU SS, CHATURVEDI N, SCHALKWIJK CG, STEHOUWER CD, EBELING P, FULLER JH: Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients. J Diabetes Complications 2006; 20: 188-95.
26. POREDOS P: Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 2004; 9: 46-54.
27. MONTAUBAN VAN SWIJNDREGT AD, DE LANGE EE, DE GROOT E, ACKERSTAFF RG: An in vivo evaluation of the reproducibility of intima-media thickness measurements of the carotid artery segments using B-mode ultrasound. Ultrasound Med Biol 1999; 25: 323-30.
28. BENEDETTO FA, TRIPEPI G, MALLAMACI F, ZOCCALi C: Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD. J Am Soc Nephrol 2008; 19: 757-63.
29. MANCIA G, DE BG, DOMINICZAK A et al.: 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-62.